menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Biogen blueprints headquarters move to new digs in Cambridge

    FIERCE PHARMA

    Biogen`s Biologic Tysabri Receives Suppl Approval in US

    FDA

    NICE again rejects Alzheimer`s drugs from Lilly and Biogen/Eisai

    FIERCE PHARMA

    EU Reaffirms Positive Opinion for Eisai-Biogen Alzheimer’s Drug

    REUTERS

    Biogen and Stoke Strike Dravet Syndrome Co-Development Deal

    BIOSPACE

    Biogen taps Royalty for $250M to fund phase 3 lupus

    REUTERS

    Biogen axes asset from $7.3B buyout, plus Alzehimer’s

    FIERCE BIOTECH

    Genentech’s Gazyva Shows Superiority in Active Lupus Nephritis

    BUSINESSWIRE

    Sage rejects Biogen`s $469 million takeover offer

    BIOSPACE

    FDA OKs monthly maintenance dosing for Eisai/Biogen`s AD drug

    PRESS RELEASE

    Biogen Trims Research Workforce, SMA Drug Accepted for Review

    BIOSPACE

    FDA & EMA Accept Higher Dose Nusinersen Applications In SMA

    GLOBENEWSWIRE

    Biogen CEO sees no burning need for more acquisitions

    REUTERS

    FDA Accepts LEQEMBI BLA for Subcutaneous Maintenance Dosing for AD

    PR NEWSWIRE

    Biogen proposes to buy stake in Sage in $442 million deal

    REUTERS

    Chung-Ang Researchers Reveal Transfer RNA`s Role In Cancer Progress

    PR NEWSWIRE

    n-Lorem Hosts Nano-Rare Colloquium With 750+ Attendees

    BUSINESSWIRE

    Private Medicare Plans Must Cover Biogen`s ALS Drug

    REUTERS

    Leqembi (Lecanemab) Launched in South Korea for Alzheimer`s Disease

    PR NEWSWIRE

    Dapirolizumab Pegol Ph 3 Data Shows Lupus Disease Activity Reduction

    GLOBENEWSWIRE

    EU backs Eisai-Biogen Alzheimer`s drug after initial rejection

    REUTERS

    EU regulators endorse meds from BMS, J&J, Eisai and more

    FIERCE PHARMA

    UCB & Biogen’s dapirolizumab pegol paves path for lupus treatment

    EXPRESSPHARMA

    5 Reasons Biogen’s Shares Have Dropped 36% in 2024

    BIOSPACE

    Biogen buys in to molecular glues with deal worth up to $1.45B

    FIERCE BIOTECH

    Biogen raises profit guidance as Leqembi`s launch trudges on

    FIERCE PHARMA

    Eisai Presents Lecanemab Long-Term Data at CTAD Conference

    GLOBENEWSWIRE

    Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

    GLOBENEWSWIRE

    Biogen and Neomorph Collaborate on Molecular Glue Degraders

    GLOBENEWSWIRE

    CFO Michael McDonnell to Retire in February 2025

    #N/A

    Biogen Reports Positive IGNAZ Phase 2 Results in IgA Nephropathy

    GLOBENEWSWIRE

    Biogen To Present Data At CTAD 2024 Annual Conference

    GLOBENEWSWIRE

    Biogen Announces New Data Presentations At ASN Kidney Week

    GLOBENEWSWIRE

    Suboptimal Leqembi vials could create millions in waste

    FIERCE PHARMA

    Suboptimal Leqembi vials could create millions in waste: study

    FIERCE PHARMA

    Biogen reports promising results for higher dose of Spinraza

    PRESS RELEASE

    Biogen Receives FDA Breakthrough For Felzartamab In AMR In Kidney

    GLOBENEWSWIRE

    New Nusinersen Data Presented At World Muscle Society Congress

    GLOBENEWSWIRE

    Positive Ph3 Results For UCB/Biogen`s Dapirolizumab Pegol

    PR NEWSWIRE

    Biogen And Investors Want US Court To Clarify Class Certification

    REUTERS

    Biogen cans SAGE-324 collaboration after essential tremor fail

    FIERCE BIOTECH

    Sage Therapeutics Ends Biogen Collaboration On SAGE-324

    BUSINESSWIRE

    Biogen-UCB`s lupus drug meets main goal of late-stage trial

    PRESS RELEASE

    Samsung Bioepis and Biogen Receive Positive CHMP

    GLOBENEWSWIRE

    Biogen Board Appoints Two New Independent Directors

    GLOBENEWSWIRE

    Bio-Thera And Biogen Publish TOFIDENCE Phase 3 Trial Data

    PR NEWSWIRE

    C4 Therapeutics Delivers Second Development Candidate To Biogen

    GLOBENEWSWIRE

    Biogen Reports Positive Results For Higher Dose Nusinersen

    GLOBENEWSWIRE

    Biogen to Seek Approval for High-Dose Spinraza After Positive Trial Results

    FIERCE PHARMA

    IGC Pharma Advances IGC-AD1 Toward Trials for Alzheimer`s Anti-Amyloid Treatment

    BUSINESSWIRE

    New Alzheimer`s drug deemed too costly for UK`s state-run health service

    REUTERS

    BioArctic Comments On Lecanemab Approval Rumors In Britain

    PR NEWSWIRE

    Biogen Sued Over Alleged PBM Kickbacks For Tecfidera

    FIERCE PHARMA

    Incyte`s blood cancer drug succeeds late-stage trial

    REUTERS

    Metagenomi axes ALS program after seeing Biogen and Ionis flounder

    FIERCE BIOTECH

    OpenFold AI Consortium Welcomes Six New Members

    BUSINESSWIRE

    Immunic Reports Q2 2024 Results And Provides Corporate Update

    PR NEWSWIRE

    Sangamo secures $50M upfront in neurodegenerative pact with Roche`s Genentech

    FEIRCE BIOTECH

    Sangamo secures $50M upfront in neurodegenerative pact with Roche`s Genentech

    FIERCE BIOTECH

    Biogen Keeps Biosimilars As Leqembi Advances Amid Business Shift

    FIERCE PHARMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.